Ohio State Navbar

Second-Line Chemotherapy Superior To Erlotinib For EGFR Wild-Type NSCLC


Dr. Greg Otterson offers his perspective on a new study for non-small cell lung cancer. He writes: The TAILOR trial, a comparison of erlotinib vs. docetaxel as second-line treatment of patients with advanced non–small cell lung cancer (NSCLC) with wild-type EGFR is an important study. Since 2000, there have been many published studies of second-line treatment in unselected patients (with respect to EGFR mutations) with NSCLC demonstrating benefit, leading to approval of three agents — docetaxel, pemetrexed (Alimta, Lilly) and erlotinib. As the authors point out, the initial treatment of patients with EGFR-sensitizing mutations is either erlotinib or gefitinib (Iressa, AstraZeneca), and soon perhaps afatinib (Gilotrif, Boehringer Ingelheim).

HemOnc Today